Veliparib and Temozolomide in Treating Patients With Acute Leukemia
Phase 1 Completed
66 enrolled
Pevonedistat, Azacitidine, Fludarabine Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
Phase 1 Completed
12 enrolled 16 charts
Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorders
Phase 1 Completed
12 enrolled
Testing Nivolumab in Combination With Decitabine and Venetoclax in Patients With Newly Diagnosed TP53 Gene Mutated Acute Myeloid Leukemia
Phase 1 Completed
1 enrolled 8 charts
Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Phase 2/3 Completed
76 enrolled 16 charts
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
Phase 3 Completed
144 enrolled 8 charts
Pinometostat and Azacitidine in Treating Patients With Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemia With 11q23 Rearrangement
Phase 1/2 Completed
1 enrolled 6 charts
Specialized Blood Cell Transplants for Cancers of the Blood and Bone Marrow
Phase 2 Completed
202 enrolled 17 charts
Combination Chemotherapy and Dasatinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
Phase 2 Completed
61 enrolled 14 charts
Decitabine With or Without Bortezomib in Treating Older Patients With Acute Myeloid Leukemia
Phase 2 Completed
165 enrolled 13 charts
Pembrolizumab and Decitabine for Refractory or Relapsed Acute Myeloid Leukemia
Phase 1/2 Completed
10 enrolled 12 charts
Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia
Phase 2 Completed
68 enrolled 11 charts
Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia
Phase 2 Completed
41 enrolled 11 charts
Acute Myeloid Leukemia T Cell Depletion to Improve Transplants in Adults With Acute Myeloid Leukemia (BMT CTN 0303)
Phase 2 Completed
47 enrolled 20 charts
Peptide Vaccinations to Treat Patients With Low-Risk Myeloid Cancers
Phase 2 Completed
10 enrolled 7 charts
Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant
Phase 1 Completed
71 enrolled
Methods to Enhance the Safety and Effectiveness of Stem Cell Transplants
Phase 2 Completed
116 enrolled 14 charts
A Case-Cohort Study of Hematopoietic Malignancies and Related Disorders and Lung Cancer in Benzene-Exposed Workers in China
Completed
3,260 enrolled
Pilot Study of Leuprolide to Improve Immune Function After Allogeneic Bone Marrow Transplantation
Phase 2 Completed
76 enrolled 16 charts
Mismatched Donor Lymphocyte Infusions for Relapsed Disease Following Allogeneic Stem Cell Transplantation
Phase NA Completed
8 enrolled 12 charts
Pomalidomide After Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Phase 1 Completed
50 enrolled
Preventing Stem Cell Transplant Complications With a Blood Separator Machine
Phase 1/2 Completed
41 enrolled 21 charts
Immunosuppressive Preparation Followed by Blood Cell Transplant for the Treatment of Blood Cancers in Older Adults
Phase 2 Completed
28 enrolled
Clofarabine Followed By Lenalidomide for High-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia
Phase 1 Completed
4 enrolled
Bone Marrow Transplant Studies for Safe and Effective Treatment of Leukemia
Phase NA Completed
41 enrolled
AZD2171 to Treat Children and Adolescents With Solid Tumors or Acute Myelogenous Leukemia
Phase 1 Completed
18 enrolled
Biomarkers for Personalized Early Assessment of Response During Salvage Chemotherapy in People With Relapsed or Refractory Acute Myeloid Leukemia (PEARL15)
Completed
15 enrolled
MS-275 and Azacitidine in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia
Phase 1 Completed
63 enrolled
Vorinostat, Azacitidine, and Gemtuzumab Ozogamicin for Older Patients With Relapsed or Refractory AML
Phase 1/2 Completed
52 enrolled 12 charts
Decitabine as Maintenance Therapy After Standard Therapy in Treating Patients With Previously Untreated Acute Myeloid Leukemia
Phase 2 Completed
546 enrolled 5 charts
Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203)
Phase 2 Completed
279 enrolled 28 charts
Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia
Phase 3 Completed
754 enrolled 20 charts
The Role of Cyclosporine in Blood Cell Transplants With T-Cell Add-Back for Blood Cancers
Phase 2 Completed
102 enrolled
Experimental Bone Marrow Transplant Protocol
Phase 2 Completed
14 enrolled
AKT Inhibitor MK-2206 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Phase 2 Completed
19 enrolled 8 charts
Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
Phase 2 Completed
78 enrolled 10 charts
Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies
Phase 2 Completed
12 enrolled 11 charts
Stem Cell Transplantation for Patients With Cancers of the Blood
Phase 2 Completed
61 enrolled 6 charts
Ultra-Low Dose IL-2 Therapy as GVHD Prophylaxis in Haploidentical Allogeneic Stem Cell Transplantation
Phase 1 Completed
24 enrolled
Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia
Phase 2 Completed
52 enrolled 17 charts
PXD101 in Treating Patients With Acute Myeloid Leukemia
Phase 2 Completed
12 enrolled 6 charts
Ipilimumab in Treating Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia
Phase 1 Completed
42 enrolled
Azacitidine in Combination With Mitoxantrone, Etoposide Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Phase 1 Completed
24 enrolled
Decitabine, Vorinostat, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
Phase 1 Completed
17 enrolled
Alvocidib, Cytarabine, and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
Phase 2 Completed
172 enrolled 12 charts
MS-275 and GM-CSF in Treating Patients With Myelodysplastic Syndrome and/or Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphocytic Leukemia
Phase 2 Completed
24 enrolled 5 charts
Safety of Peptide Vaccination for Patients With Myelodysplastic Syndrome
Phase 1 Completed
9 enrolled
Wilm's Tumor 1 Protein Vaccine to Treat Cancers of the Blood
Phase 1/2 Completed
10 enrolled 21 charts
Cediranib Maleate in Treating Patients With Relapsed, Refractory, or Untreated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Phase 2 Completed
39 enrolled 9 charts
Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia
Phase 2 Completed
197 enrolled 8 charts